Genomic Health Stock Hits New 52-Week High (GHDX)

NEW YORK ( TheStreet) -- Genomic Health (Nasdaq: GHDX) hit a new 52-week high Thursday as it is currently trading at $29.57, above its previous 52-week high of $29.52 with 92,930 shares traded as of 12:25 p.m. ET. Average volume has been 182,100 shares over the past 30 days.

Genomic Health has a market cap of $785.7 million and is part of the health care sector and health services industry. Shares are up 14.1% year to date as of the close of trading on Wednesday.

Genomic Health, Inc., a molecular diagnostics company, focuses on the development and global commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. The company has a P/E ratio of 110.4, below the average health services industry P/E ratio of 120.9 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Genomic Health as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, expanding profit margins, solid stock price performance and impressive record of earnings per share growth. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full Genomic Health Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

If you liked this article you might like

5 Stocks to Trade for Big Breakout Gains

Genomic Health (GHDX): Today's Weak On High Volume Stock

Genomic Health (GHDX) Strong On High Relative Volume Today

Today's Weak On High Volume Stock: Genomic Health (GHDX)

Analysts' Actions -- Apple, American Eagle, General Motors, Under Armour and More